News Release：2024 | Eisai Co., Ltd.
Oct 30, 2024 · eisai completes a major renovation of tsukuba research laboratories as a global drug discovery center aiming for connecting human and human, and data, and the world. april 4, 2023. eisai publishes long-term health outcomes using simulation model of lecanemab using phase 3 clarity ad data in peer-reviewed neurology and therapy journal
FDA Approves LEQEMBI™ (lecanemab-irmb) Under the ... - Eisai …
Jan 7, 2023 · Eisai plans to file for marketing authorization applications of lecanemab in Japan and Europe by the end of Eisai’s FY2022. Since July 2020 Eisai’s Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing.
Notification of Ransomware Incident | News Release：2023 - Eisai …
Jun 6, 2023 · A ransomware incident that encrypted some of Eisai Group’s servers was detected late night on Saturday, June 3, Japan time. We immediately implemented our incident response plan and launched an investigation with the aid of our cybersecurity partners.
LECANEMAB CONFIRMATORY PHASE 3 CLARITY AD STUDY MET
Sep 28, 2022 · eisai's news release lecanemab confirmatory phase 3 clarity ad study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1,795 participants with early alzheimer’s disease is posted.
EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 …
Nov 30, 2022 · Eisai is hosting a live webcast of the scientific session featuring the lecanemab presentations, which can be viewed live on the investors section of the Eisai Co., Ltd. website. The content will be available on demand afterward.
New Clinical Data Demonstrates Three Years of ... - Eisai Co., Ltd.
Jul 31, 2024 · Eisai's news release New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at AAIC 2024 is posted.
News Release：2021 | Eisai Co., Ltd.
Dec 16, 2021 · Eisai’s anti-microtubule binding region (MTBR) tau antibody E2814 previously selected as the first investigational therapy among anti-tau drugs for the DIAN-TU Tau Next Generation trial. November 4, 2021
EISAI ANNOUNCES MOVE TO SOLO DEVELOPMENT AND …
Jul 1, 2024 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug ...
A research-based pharmaceutical company | Eisai US
5 days ago · eisai presents latest clinical findings suggesting inhibition of tau propagation by anti-mtbr tau antibody e2814 at the 17th clinical trials on alzheimer's disease conference (ctad) Read more > latest news
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker ...
Jul 20, 2023 · This news release contains forward-looking statements about the potential benefits, safety and efficacy of LEQEMBI; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer's disease; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of ...